Arbaclofen Placarbil Decreases Reflux With Good Tolerability in Patients With Gastroesophageal Reflux Disease (Am J Gastroenterol 2010;105:1266-1275) by Kim, Gwang Ha
JNM Journal of Neurogastroenterology and Motility 
Journal Club
444
J Neurogastroenterol Motil,  Vol. 16  No. 4 October,  2010 
DOI: 10.5056/jnm.2010.16.4.444
ⓒ 2010 The Korean Society of Neurogastroenterology and Motility
J Neurogastroenterol Motil,  Vol. 16  No. 4 October,  2010
www.jnmjournal.org
Arbaclofen Placarbil Decreases Reflux With Good 
Tolerability in Patients With Gastroesophageal 
Reflux Disease
(Am J Gastroenterol 2010;105:1266-1275)
Received: August 26, 2010 Revised: September 14, 2010 Accepted: September 17, 2010
CC This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons. 
org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work 
is properly cited.
*Correspondence: Gwang Ha Kim, MD, PhD
Department of Internal Medicine, Pusan National University School of Medicine, 1-10 Ami-dong, Seo-gu, Busan 602-739, Korea
Tel: +82-51-240-7869, Fax: +82-51-244-8180, E-mail: doc0224@pusan.ac.kr
Financial support: None.
Conflicts of interest: None.
Gwang Ha Kim, MD, PhD
Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea
Summary 
Arbaclofen placarbil (AP), previously designated as XP19986, 
is a novel transported prodrug of the active R-isomer of baclofen, 
which overcomes the pharmacokinetic limitations of racemic ba-
clofen.
1 AP is efficiently absorbed by high-capacity active trans-
port pathways expressed throughout the gastrointestinal (GI) tra-
ct, and rapidly metabolized to release R-baclofen after the absorp-
tion. 
This multicenter, randomized, double-blind, crossover study 
comparing single doses of AP with placebo was conducted to as-
sess the efficacy and safety of AP for decreasing meal-induced re-
flux episodes in patients with gastroesophageal reflux disease 
(GERD).
2
Different patients were enrolled at each of 4 escalating AP 
doses: 10, 20, 40 and 60 mg. A total of 50 patients were treated 
and the efficacy analysis included 44 patients who completed the 
protocol and had technically satisfactory impedance/pH data. 
There was a statistically significant decrease in reflux episodes 
over 12 hours after treatment with AP compared with placebo (p
= 0.01). The mean ± SD number of reflux episodes over 12 
hours after AP treatment was 50.5 ± 27.2, with a mean reduc-
tion of 10.4 ± 23.9 episodes (17%) compared with placebo (60.9
± 35.3). Only acid reflux episodes were statistically decreased 
after treatment with AP. Heartburn events associated with reflux 
were reduced during treatment with AP compared with placebo 
(12.9 ± 11.9 vs 16.7 ± 18.2, p = 0.03). AP seemed to be the 
most efficacious in the 60 mg dose group, and was well tolerated 
at all dose levels.
Comment
Up to 40% of GERD patients fail to completely respond 
symptomatically to standard proton pump inhibitor doses.
3 
GERD is commonly associated with transient lower esophageal 
sphincter relaxations (TLESRs), which are relaxations not re-
lated to swallowing.
4 TLESRs are triggered by gastric dis-
tension, mediated by mechanosensitive vagal afferent neurons 
terminating in the brainstem, resulting in a vago-vagal reflex mo-
tor pattern that also involves inhibition of the crural diaphragm 
and longitudinal muscle contractions in the distal esophagus.
5
Racemic baclofen, an agonist of γ-aminobutyric acid recep-
tor, has been shown to decrease reflux through the inhibition of Arbaclofen Placarbil Decreases Gastroesophageal Reflux
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TLESRs and the augmentation of lower esophageal sphincter 
pressure. A study using impedance/pH found that 40 mg of ba-
clofen significantly reduced total reflux episodes and associated 
GERD symptoms over a period of 2 hours following a refluxo-
genic meal given 1 hour after the treatment.
6 Another study show-
ed that administration of baclofen, 10 mg, 4 times a day (q.i.d.), 
decreased reflux episodes by 51% over 24 hours.
7 In the same 
study, the reduction in reflux episodes and reflux symptoms was 
maintained after 4 weeks of treatment with baclofen, 10 mg q.i.d., 
compared with placebo. This observation suggests that the reduc-
tion in reflux episodes and associated symptoms after a single 
dose of AP may also result in clinically relevant benefits through 
4 weeks of treatment in subsequent studies.
However, the limitations of baclofen include a short half-life 
requiring frequent dosing, and adverse effects including seda-
tion, dizziness, nausea and fatigue.
8 Orally administered baclofen 
is absorbed from the lumen of the GI tract through an active 
transport system found predominantly in the proximal small 
bowel. However, the lack of significant absorption in the lower 
intestine has precluded the development of a sustained-release 
formulation.
AP is developed in a sustained-release formulation, allowing 
for decreased dosing frequency with reduced fluctuation in R-ba-
clofen exposure due to its absorption in the lower GI tract.
9 This 
may lead to improved efficacy and a decreased incidence of ad-
verse effects compared with racemic baclofen. 
Therefore, this present study assessed the efficacy of AP for 
decreasing the total number of reflux episodes in patients with 
GERD, in whom substantial baseline incidence of meal-induced 
reflux was confirmed by impedance/pH measurements. The au-
thors found that AP significantly reduced the total number of re-
flux episodes over 12 hours by 17% compared with placebo and 
AP seemed to be most efficacious in the 60 mg dose group, which 
is comparable in magnitude to those observed in previous studies 
of baclofen.
In this study, AP had a favorable tolerability and safety pro-
file across the evaluated doses. There was no statistically sig-
nificant difference in the number of patients experiencing adverse 
events after taking the active drug compared with placebo. 
Although the number of patients in this study was small, AP 
could be considered in proton pump inhibitor-refractory GERD 
patients in the near future.
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